Research programme: mRNA based vaccines - CureVac

Drug Profile

Research programme: mRNA based vaccines - CureVac

Alternative Names: CV-7302; RNActive® cancer immunotherapy; RNActive® infectious disease vaccines; RNActive® prophylactic vaccines

Latest Information Update: 19 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CureVac
  • Class Antineoplastics; Cancer vaccines; Influenza A vaccines; RNA vaccines; Rotavirus vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Influenza A virus infections; Respiratory syncytial virus infections
  • Research Cancer; HIV infections; Malaria; Rotavirus infections
  • No development reported Infections

Most Recent Events

  • 13 Feb 2018 Early research in Malaria (Prevention) in Germany (unspecified route)
  • 10 Jan 2018 CureVac plans a phase I trial of RNActive® prophylactic vaccine (Prevention) for seasonal Influenza virus infections in 2018
  • 10 Jan 2018 Preclinical development in Influenza-A-virus-infections(Prevention) is ongoing Germany (Intradermal, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top